Most material SEC filings — August 14, 2026

Greenlane Holdings held 81.3M BERA units (cost basis $70.2M, fair value $16.4M) as of June 30, 2026, up from 51.7M units at year-end 2025; BERA-per-share increased 37% to 117 units. However, the company's market capitalization (~$1.0M) fell below the proposed $5.0M Nasdaq Capital Market minimum listing requirement approved July 22, 2026, creating immediate delisting risk. Q2 net loss was $(24.8)M, driven by $(19.1)M non-cash fair value decline in digital assets.

SES AI Corp filed an 8-K on August 14, 2026 reporting Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard. The filing does not specify which exchange listing rule was violated, the exact deficiency, or a remediation timeline. This represents a critical threat to the company's public market status and ability to raise capital.

On August 12, 2026, Reed's Inc. received notice from NYSE American that it is below compliance with listing standards due to a stockholders' deficit of $(1.5)M and five consecutive years of losses. The company submitted a remediation plan on June 26, 2026, which NYSE American accepted on August 12, 2026. Reed's has until November 29, 2027 to regain compliance or face delisting proceedings; shares continue trading during this period subject to quarterly monitoring.

Shareholders of both Real Brokerage (NASDAQ: REAX) and RE/MAX Holdings (NYSE: RMAX) voted to approve Real's acquisition of RE/MAX Holdings on August 14, 2026. Real shareholders approved by 99.0% vote; RE/MAX Holdings shareholders approved by 78.8% voting power. The combined entity, Real REMAX Group, will operate ~180,000 real estate professionals across 120+ countries with pro forma 2025 revenue of $2.3B and Adjusted EBITDA of $157M. Closing expected within weeks pending final British Columbia Supreme Court approval.

On August 13, 2026, Adagio Medical Holdings received notice of delisting or failure to satisfy continued listing rules/standards. The filing provides no specific detail on the reason, timeline, remediation plan, or financial impact. This is a critical corporate event for a $7.0M market-cap company.

Scilex committed to: (1) $120M upfront cash to Datavault AI Inc. (dated 26 Apr 2026) for 30% revenue share on quantum-edge network, capped at $1.2B cumulative payments; (2) $50M to acquire 837 BTC from Datavault's wallet ($30M upfront, $20M quarterly through Dec 2028), payable in cash or Scilex stock; (3) $100M equity investment from iHolding Group LLP (dated 3 Jul 2026) at $15/share for ~6.67M shares. All three are binding term sheets subject to definitive agreements. Scilex market cap is ~$32.4M; these commitments total $270M, approximately 8.3x current company valuation.

Sadot Group reported Q2 2026 revenue of $0.0M (vs. $246.6M YoY), gross profit of $0.0M (vs. $11.0M YoY), and net income of $35.2M ($109.16/diluted share, likely non-cash). The company faces substantial doubt about going-concern viability due to recurring losses, negative working capital, stockholders' deficit, and debt defaults. Cash stands at only $0.1M. Nasdaq compliance was conditionally restored on Aug 3, 2026, but must be re-evidenced by Sept 30, 2026 filing or delisting risk materializes. The company acquired TradeOS platform in June 2026 and generated ~$1.0M gross revenue from first commercial transactions in July 2026 (preliminary, not included in Q2 results).

Worksport Ltd filed an 8-K on August 14, 2026, disclosing Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard. The filing does not specify which exchange rule was breached, the cure period, or remediation steps. This is a critical corporate governance event for a company with market value of ~$15.6M.

Star Equity Holdings Inc. and Merger Sub-R Inc. agreed to acquire Harte Hanks Inc. (market cap ~$26.8M) in an all-stock/cash merger dated August 14, 2026. Merger consideration: $5.00 per share in cash or 0.50 shares of Parent Preferred Stock (10% Series A), subject to 50%/50% election proration with $19.2M maximum cash cap. Company equity awards (options, RSUs) converted to merger consideration; PSUs cancelled. Debt financing up to $15M via ABL Loan Agreement amendment. No specific transaction value stated but calculated as ~$37.3M gross based on 7.46M shares outstanding.

Star Equity Holdings (market cap ~$12.2M) agreed to acquire Harte Hanks, Inc. via merger dated August 14, 2026. Harte Hanks shareholders receive $5.00 per share in cash or 0.50 shares of Star Preferred Stock, with total consideration capped at $19.2M cash. Deal includes up to $15M debt financing from existing ABL credit facility. Closing contingent on stockholder approval and regulatory filings.

Axe Compute reported Q2 2026 revenue of $3.2 million (90x sequential growth from Q1's $35K), driven entirely by Axe Compute Access service contracts. Post-quarter (July 2026), the company secured $2.8 billion in total contract value across three new customers under the Axe Compute Build model, bringing 2026 total contract value to $3+ billion with expected annualized run rate of $696M upon full deployment. Customer prepayments surged to $60.8M (from $0.8M in Q1), providing capital-efficient funding for infrastructure deployment.

iSpecimen Inc. engaged IR Agency LLC on August 12, 2026, to provide marketing and news distribution services for $2,000,000, fully earned and non-refundable upon execution, payable by August 13, 2026. The agreement covers a maximum of 10 news releases over 3 months with no guarantees of stock price or volume impact. The contract heavily favors the consultant with broad liability waivers, indemnification by iSpecimen, and restrictions on iSpecimen's ability to sue.

Skye Bioscience, Inc. (Acquiror, ~$129.5M market cap) has entered into a transaction agreement dated August 14, 2026, to acquire all issued share capital of Redx Pharma Limited (Company), a UK private limited company, via a scheme of arrangement. Scheme shareholders will receive per-share consideration consisting of (i) Acquiror Common Stock (or Non-Voting Common Stock) at an exchange ratio (to be determined) and (ii) one Company Legacy CVR per share. Pre-Closing Acquiror stockholders will receive one Acquiror Legacy CVR per share held. The transaction is subject to multiple closing conditions including shareholder/stockholder approvals, court sanction in the UK, regulatory approvals, and satisfaction of net cash determination procedures. Closing is expected within two business days after conditions are satisfied.

Hydrofarm reported Q2 2026 net sales of $23.2M (down 40.9% YoY from $39.2M), with net loss of $10.6M ($2.23/share). The company faces acute financial distress: $114.4M Term Loan (classified current after Feb 2026 default on $2.8M interest payment), $6.2M cash, and break-even Free Cash Flow. Offsetting: sold Aurora Peat Products (Canada) on July 31, 2026 for $16M total ($5M as promissory note), with proceeds reducing debt. Forbearance agreement extended through Aug 31, 2026. Gross margin improved to 11.3% (vs 7.1%) but on collapsed sales. Adjusted SG&A cut 35.7% YoY.

MacroGenics and Sagard Healthcare Partners Funding Borrower SPE 2, LP amended their June 2025 Purchase and Sale Agreement effective May 1, 2026. Sagard paid MacroGenics $60 million on the amendment date, increasing the total purchase price to $130 million. The amendment also adds potential milestone payments to MacroGenics (amounts redacted) based on 2026 net sales of the royalty product under a License Agreement with Incyte, with payment due within 30 days of achievement notification.

VerifyMe reported Q2 2026 revenue of $1.9M (down 58% YoY from $4.5M), driven by September 2025 carrier partner termination and ProActive customer loss. Net loss widened to ($0.5M) from ($0.3M); Adjusted EBITDA fell to $0.0M from $0.3M. Cash position of $5.1M ($4.7M working capital) against $8.0M market cap; company is burning cash while pursuing a merger.

Outlook Therapeutics executed an underwriting agreement on August 12, 2026 to sell 55,555,556 shares of common stock at $0.98/share plus accompanying warrants (exercise price $1.10/share) at $0.01/warrant, for combined public price of $0.99 per unit. Underwriters (Piper Sandler, BTIG, Brookline Capital Markets) also received 30-day option to purchase up to 8,333,333 additional shares/warrants. Gross proceeds approximately $55M before underwriting discount of 6.94%. Lock-up period of 60 days on insiders' sales.

During 08/12–08/13/2026, reporting persons bought 650,000 shares at weighted average $2.8211 (range $2.65–$2.90) and 750,000 shares at weighted average $2.9845 (range $2.75–$3.10) in open market transactions. Total acquisition: ~1.4 million shares, approximately $4.1M in aggregate value at average ~$2.90/share.

Boxlight Corporation obtained an August 10, 2026 forbearance agreement from lender Whitehawk Capital Partners LP waiving multiple defaults: borrowing base overadvances for May–July 2026, failure to meet financial covenants for four to seven months ending April–July 2026, and non-compliance with leverage ratio requirements since May 2026. In exchange, Boxlight paid $2.25M (50% of equity proceeds from an August 6, 2026 issuance) toward loan paydown and agreed to restrict use of retained equity proceeds to working capital only. The credit agreement originated December 2021 and has been amended eleven times; this marks the eighth waiver/forbearance since inception. The company remains under post-default interest rates.

HCW Biologics filed an 8-K on 2026-08-14 disclosing Item 4.02 (non-reliance on previously issued financial statements or audit report). No specific dollar amounts, affected periods, nature of restatement errors, or remedial actions are detailed in the filing header. The actual restatement narrative is not provided in the document excerpts available.

Zentalis Pharmaceuticals completed a registered direct offering of 23,000,000 common shares at $3.50 per share (public price), generating gross proceeds of approximately $80.35 million before underwriting fees (~$5.6M at 7% discount). The underwriters—TD Securities, Guggenheim Securities, and Oppenheimer & Co.—also received a 30-day option to purchase up to 3,450,000 additional shares at the same price. Lock-up agreements restrict insiders from selling for 60 days post-prospectus. The company's market value is approximately $66.9M.

10% owner CASCADE INVESTMENT, L.L.C. (RSG) bought 363K shares (~$78.3M) on the open market (0.3% of holdings). Open-market insider purchase — historically a bullish signal.

On August 13, 2026, Optimum Communications received notice from NYSE that it failed to comply with Section 802.01C of the Listed Company Manual because its Class A common stock averaged below $1.00 over 30 consecutive trading days. The company has six months (until February 13, 2027) to regain compliance by achieving a closing price and 30-day average of at least $1.00; failure to do so will trigger NYSE delisting procedures. No immediate operational impact, but the board will consider strategic options including potential stockholder-approved actions if the stock price does not naturally recover.

FiEE, Inc. (market cap ~$6M) reported H1 2026 unaudited results: revenue $6.9M (vs. $0.05M in H1 2025, +15,298% YoY), net income $2.5M (vs. $1.0M loss in H1 2025). Gross margin expanded to 77.3% from 1.0%. Company onboarded 900+ SaaS MCN customers with $7.9M cumulative revenue, secured $2.9M software services contracts, and generated $2.9M cumulative digital authentication revenue. Completed May 2026 acquisition of Yinlian Culture (VIE Maltose Culture) to expand AI music business. Company also adopted Third Amended and Restated Bylaws and executed director termination and indemnification agreements (template forms, no specific counterparty names or amounts disclosed).

Vulcan Infrastructure & Power announced a $39.4 million strategic investment from Machine Investment Group, Atlas Holdings, Conversant Capital, and others (announced July 2026, filing dated August 14, 2026). Proceeds will redeem ~$33 million of 8.50% Senior Notes due October 2026 and fund development of its 654 MW pipeline of power and digital infrastructure assets. Q2 2026 showed deterioration: revenue $3.4M (down $9.5M YoY), net loss $9.9M (up $5.8M), adjusted EBITDA loss $6.7M (vs. $0.4M profit in Q2 2025), with $9.2M cash on hand pre-transaction.

On 2026-08-11, Teads Holding Co. received a notice of delisting or failure to satisfy continued listing rules/standards from its exchange. The 8-K Item 3.01 indicates a transfer of listing is under consideration. No specific counterparties, dollar amounts, remediation timeline, or listing destination are disclosed in the filing text provided.

BioNexus renewed CEO Su-Leng Tan Lee's contract for 3 years (Sept 2026–Aug 2029) at $35,000/month base salary ($420K/year). On Aug 13, 2026, the company issued 516,128 fully vested common shares (~$800K at $1.55/share) to five executives and directors as bonus compensation: CEO Lee received 338,709 shares ($525K), CFO Set Fui Chong 96,774 shares ($150K), and three independent directors received 16,129–32,258 shares each. All awards issued offshore under Regulation S without registration.

authID Inc. reported Q2 2026 results (10-Q filed) and announced its Board is evaluating strategic and financing alternatives including partnerships, additional financing, or sale/merger to maximize shareholder value. The company is pursuing POCs with major financial institutions and manufacturers, and integrations with ServiceNow and Zendesk, but has set no timeline for disclosure of outcomes and cancelled its earnings conference call.

House of Doge (U.S.) Inc. entered into a Securities Purchase Agreement dated August 11, 2026 with CleanCore Solutions, Inc. to purchase $5,500,000 of common stock (11,054,303 shares) and pre-funded warrants (10,945,697 warrant shares) at $0.25/share. Concurrently, House of Doge executed a Secured Short Term Demand Note with Garrington Financial Corp. for up to $5,500,000 at 12% interest (17.5% default rate) to finance the CleanCore investment. The note matures February 12, 2027, with mandatory monthly repayments of $650,000 starting September 30, 2026, and requires mandatory sales of CleanCore shares when stock trades above $0.30 to repay principal.

On August 12–13, 2026, 3i, LP sold 11,676,430 common shares at $0.3969/share (proceeds ~$4.63M) and converted 11,369,441 Series B and C preferred shares into common stock at $0.39/share. Tumim Stone sold 49,242 shares at $1.1060/share (~$54.5K). These transactions occurred within 60 days and represent significant equity restructuring by a major holder in a $4.0M market-cap company.

TOMI reported Q2 2026 revenue of $2.25M (118% YoY growth) with gross profit of $1.39M (61.7% margin). On June 29, 2026, TOMI signed a definitive merger agreement with Carbonium Core, Inc.; Carbonium shareholders will receive 19.99% of TOMZ common stock plus Series C Preferred convertible into 90% of the combined entity upon shareholder approval, contingent on $10M concurrent financing and regulatory/shareholder approval. Additionally, EPA granted unconditional AgriMist registration (EPA Reg. 90150-4) for post-harvest food safety and cannabis/hemp applications. Company reaffirmed $12M full-year 2026 guidance (113% YoY growth) and expanded sales pipeline to ~$35M.

On July 16, 2026, Jasper Therapeutics completed an all-stock acquisition of Kira Pharmaceuticals (a complement therapy company) and concurrently raised $132 million in gross proceeds via private placement of non-voting convertible preferred stock, co-led by Affinity Asset Advisors and Ikarian Capital. The combined company plans to advance KP-104 (Phase 2/3 dual complement inhibitor), briquilimab (late-stage anti-KIT antibody), and KP-701 (novel anti-CD79BxCD32B mAb), with cash runway extending to mid-2028. As of June 30, 2026, Jasper held $7.3 million in cash and reported a net loss of $2.8 million for Q2 2026.

Super League Enterprise paid Aegis Capital Corp. a Guaranteed Payment of $700,000 plus Legal Expenses of $50,000 (total $750,000 immediately), with a conditional Contingent Payment of $300,000, to obtain: (1) irrevocable waiver of Aegis's Right of First Refusal on transactions; (2) waiver of all tail financing fee rights under five prior underwriting and placement agreements; (3) complete release of all claims against Super League. The agreement dated July 29, 2026 also waives Aegis consent rights on settlements and requires Super League to maintain warrant exercise fee rights per Schedule I.

Quince completed a stock-for-stock merger with Orphai Therapeutics on May 18, 2026, acquiring LAM-001 (inhaled rapamycin) for PH-ILD, BOS, and SAPH. Concurrent private placement raised $115M gross ($103.6M net), with potential $83M additional from warrant exercise. Cash position is $116M as of June 30, 2026, expected to fund operations through end of 2028. Q2 2026 net loss was $75.5M ($12.31/share on 978,022 shares); LAM-001 Phase 2b PH-ILD data expected Q1 2028, Phase 2 BOS data expected Q1 2027.

On August 3, 2026, Obsidian Therapeutics completed a reverse merger with Galera Therapeutics to form a combined company under Obsidian's name. Concurrently, on July 31, 2026, a PIPE financing closed generating $350.0M gross proceeds from qualified institutional buyers and accredited investors purchasing Series C Preferred Stock of Galera. Post-transaction, Legacy Obsidian shareholders own ~51.5% of combined company common stock, Galera shareholders own ~1.3%, and PIPE investors own ~47.2%. The combined entity began trading on Nasdaq under ticker OBX on August 4, 2026.

VirTra reported H1 2026 revenue of $9.2M (down 35% YoY from $14.1M) and net loss of $1.6M (vs. $1.4M profit YoY). Q2 revenue was $5.8M (down 17% YoY). Backlog stood at $24.9M ($13.2M capital, $3.8M service, $7.9M STEP). The company acquired an Orlando dual-building campus and was accepted into the U.S. Army Marketplace across three capability areas. Adjusted EBITDA swung to negative $0.4M for H1 (vs. positive $2.4M YoY).

Q2 2026: Digi Power X generated $6.6M revenue (including $1.1M from GPU rental in five weeks), net loss $14.4M, positive Adjusted EBITDA $3.3M. The company secured a 10-year AI data center contract worth $1.1B (~$140M annualized), expandable to $2.5B. Cash position $150M (post-August 14), zero debt; targets $250M–$300M annualized revenue by Q3 2027 from Alabama Tier III data center (40 MW by Mar 2027) and GPU platform expansion (10 MW planned in 2027). Also holds ~48% of subsidiary USDC (valued $125M pre-money in Q2 2026).

TuHURA Biosciences (market cap ~$111M) announced a $50 million term credit facility from its largest shareholder in April 2026, bearing 12% annual interest with 5-year maturity (April 2031). The company has drawn $5.7M to date ($2.15M after June 30, 2026) and holds $1.0M cash at Q2 2026 quarter-end. The facility extends runway into 2028 and supports Phase 1b/2 trials for TBS-2025 (VISTA inhibitor in AML) and ongoing Phase 3 development of IFx-2.0 (innate immune agonist for Merkel cell carcinoma).

LanzaTech reported Q2 2026 revenue of $9.0M (flat YoY) but net income of $184.3M, primarily from a $208.1M non-cash unrealized gain on its 8.38% stake in Shougang LanzaTech (SGLT), which IPO'd on Hong Kong Exchange in June at $750M valuation, later rising to ~$1.32B. Operating expenses fell 67% to $11.7M from $35.1M YoY due to headcount reductions and cost optimization. Adjusted EBITDA loss improved to $(7.6)M from $(29.7)M. Cash increased to $48.9M from $17.1M after $50M equity raise.

Galectin Therapeutics' Chairman Richard Uihlein converted $105.8M in debt ($91.0M principal + $14.8M accrued interest) into 34,376,167 common shares, effective July 31, 2026, eliminating five of six credit facilities. Simultaneously, the FDA agreed on Phase 3 trial design for belapectin in MASH cirrhosis with portal hypertension; the company expects to submit the registrational protocol in Q3 2026. Cash position: $13.2M as of June 30, 2026, with $10M additional credit available.

PMV Pharmaceuticals completed enrollment of platinum-resistant/refractory ovarian cancer patients in the PYNNACLE Phase 2 monotherapy trial for rezatapopt (PC14586), a p53 Y220C reactivator. The company plans to submit an NDA for accelerated approval in Q1 2027. Cash position declined to $79.4M (June 30, 2026) from $112.9M (Dec 31, 2025), providing runway through Q2 2027; operating cash burn for H1 2026 was $34.3M.

Outlook Therapeutics obtained FDA approval for LYTENAVA (bevacizumab-vikg), an ophthalmic bevacizumab for wet AMD, and is planning U.S. commercial launch by end of 2026. Management projects potential peak sales exceeding $500M annually by 2030. Post-quarter (August 2026), the company closed a public offering of 55.6M shares and 55.6M warrants at $0.99/share for ~$51.1M net proceeds. Q3 FY2026 net loss was $20.3M ($0.15/share); adjusted net loss $10.9M ($0.09/share). Cash on hand at quarter-end was $11.2M.

Aptevo reported Q2 2026 cash of $9.8M (matching entire market cap). Mipletamig showed 87% clinical benefit rate and 81% remission rate in 31 frontline AML patients in Phase 1b RAINIER trial; company targets Phase 2 dose selection by year-end 2026 and regulatory interaction in Q1 2027. Non-dilutive $1.5M grant from Andy Hill Cancer Research Endowment funds APVO451 trispecific development. Aptevo entered 50/50 collaboration with Niowave for up to three radiopharmaceutical programs; Niowave made equity investment at closing representing 7.9% stake with potential to reach 19.99%.

FDA granted accelerated approval to TUDRIQEV (vusolimogene oderparepvec-wtpg) in combination with nivolumab for unresectable advanced cutaneous melanoma on August 6, 2026; Replimune completed $150M financing ($141M net proceeds received in August 2026) to fund commercial launch and IGNYTE-3 confirmatory trial; Michelle DiNapoli appointed Chief Commercial Officer effective August 18, 2026, bringing 25+ years oncology commercialization experience.

Aptevo Research and Development LLC (Aptevo's subsidiary) entered into a 50/50 cost-sharing collaboration with Niowave, Inc. dated May 25, 2026, to develop oncology radiopharmaceutical products combining Aptevo's proprietary molecules with Niowave's Actinium-225 radioisotopes. Concurrently, Niowave purchased 98,522 shares of Aptevo common stock at an initial price (price redacted [***]), with rights to purchase up to 150,574 additional shares during a 3-year exercise period, capped at 19.99% beneficial ownership and $8.00 warrants. Development costs split equally; revenue from third-party licensees allocated 50/50 (or per cost-share ratio if unequal). Terminating party receives 2–8% royalty on net sales depending on development stage at exit.

Mithaq Capital SPC transferred 500,000 restricted shares of Children's Place common stock to Muhammad Asif Seemab (Executive Vice-Chairman, President, Interim CEO) on August 11, 2026. Vesting occurs in three tranches of ~166,667 shares each upon market capitalization milestones: $265M (Tranche 1), $400M (Tranche 2), and $600M (Tranche 3). Unvested shares forfeit after 5 years unless extended. Current company market value is ~$38M.

Professional Diversity Network (market cap ~$5.3M) completed the divestiture of NAPW Network and IAW, Inc. in July 2026 to focus on core businesses. Q2 2026 revenues declined $460K (28%) to $1.181M versus $1.641M in Q2 2025, driven by 33.8% decline in TalentAlly recruitment services ($300K) and 21.3% drop in RemoteMore software development ($142K). Net loss from continuing operations widened to $1.716M (Q2 2026) from $492K (Q2 2025), primarily due to $1.156M in amortization of 28 musical work copyrights acquired since September 2025. Working capital deficit improved to $0.9M from $4.0M at year-end 2025.

MySize (NASDAQ: MYSZ, $4M market cap) reported Q2 2026 revenue of $3.07M (+53% YoY) and H1 revenue of $5.46M (+57% YoY). However, net loss expanded to $1.75M in Q2 (vs. $450K prior year) and gross margin compressed to 31.7% (vs. 56.0%) due to higher e-commerce mix. Management now prioritizes contribution margin improvement, operating leverage, and cash efficiency over growth; Q2 operating cash burn was $1.97M H1 (improved from $2.31M prior year). Company held only $453K cash as of June 30, 2026.

Moleculin reported positive interim Phase 2/3 MIRACLE trial data showing complete remission (CR) rates of 43% and 36% in two Annamycin arms versus 12% control in relapsed/refractory AML (n=45). The company raised $9.3M in post-quarter financing and expects cash to fund operations into Q1 2027. Part A enrollment (90 patients) targeted for September 2026 completion with data readout December 2026–February 2027; Part B initiation expected H1 2027.

Clene Inc. announced plans to submit a New Drug Application for CNM-Au8 under FDA accelerated approval pathway in early Q4 2026 for ALS treatment, supported by new biomarker analyses showing NfL decline/stabilization correlates with survival and functional benefits. In May 2026, the company closed a $7.0 million registered direct offering to a single investor and extended maturity dates on $10.0 million and $1.5 million senior secured convertible debt facilities to August 2027. Cash position improved to $9.7 million as of June 30, 2026, from $5.2 million at year-end 2025, with operating runway projected through late Q4 2026.